Recombinant human IgG1 monoclonal antibody containing anti-inflammatory drug used for inhibition of tumor necrosis factor (TNF) is referred as adalimumab. Adalimumab inhibit activation of TNF- α receptors by binding to TNF- α. Activation of TNF- α is observed to be significant in producing autoimmune disease related inflammatory reactions. Common side effects of adalimumab include redness, swelling, itching, rash, hemorrhage, bruising and pain at the site of injection. In addition, side effects such as upper respiratory tract infections (RTI), nausea, vomiting, anaphylaxis, hepatitis B infection, increased risk of heart failure, liver injuries, internal bleeding, psoriasis and headache are some more side effects of adalimumab observed in some cases.
Adalimumab is a patented product of Abbott Biotechnology Ltd. was invented by Jochen G. Salfeld et al. Adalimumab is available in the market with the trade name of HUMIRA. The U.S. Food and Drug Administration (FDA) approved adalimumab for indications including Crohn's disease, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, juvenile idiopathic arthritis and rheumatoid arthritis in December, 2002. HUMIRA is a parenteral formulation intended to inject subcutaneously. HUMIRA is available as a single use pre-filled syringe, single use pain and single use vial. Prefilled syringe and single use pens are available in 1ml quantity. While, single use vials are available in 2 ml quantity.
Rising prevalence of arthritis is one of the prime drivers for the growth of the global adalimumab market. Women population is at higher risk of arthritis owing to excess loss of body calcium as compared to male population. Further, increasing sedentary lifestyle is fueling the growth of arthritis prevalence globally. For instance, according to Centre of Disease Control and Prevention, the U.S., approximately 52.5 million adults in the U.S. are reported to have arthritis, rheumatoid arthritis, gout, lupus and fibromyalgia. While on the other hand, high cost is one of the major factors restraining the growth of the global adalimumab market.
Geographically, the global adalimumab market is segmented into North America, Europe, Asia Pacific and Rest of the World (RoW). North America comprises adalimumab market for the U.S. and Canada. Europe comprises cumulative market of adalimumab in Germany, Italy, France, Spain, and Rest of Europe (RoE). Asia Pacific comprises cumulative market of adalimumab in China, India, Australia, New Zealand and rest of Asia Pacific (RoAPAC). Rest of the World (RoW) comprises adalimumab market in Latin America, Middle East and Russia. Presently, North America and Europe are leading the global adalimumab market. Factors such as availability of well structured regulatory framework, advanced healthcare infrastructure and reimbursement coverage are driving the adalimumab market in North America and Europe market. Asia Pacific adalimumab market is anticipated to show significant growth in the near future. Factors such as rapidly developing healthcare infrastructure, rising disposable income and government initiatives to strengthen healthcare sector in respective country are driving the adalimumab market in Asia Pacific. China and India account for one of the largest population pool in the world. Thus, geriatric population pool in these countries is expected to grow with passing time. Significant presence of geriatric population is anticipated to fuel the demand for anti-arthritis drugs.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. This report provides comprehensive analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for upcoming years
This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point analysis for changing competitive dynamics
- It provides a forward looking perspective on different factors driving or restraining market growth
- It provides a six-year forecast assessed on the basis of how the market is predicted to grow
- It helps in understanding the key product segments and their future
- It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments
- It provides distinctive graphics and exemplified SWOT analysis of major market segments
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.